[Andrenogenital syndrome (author's transl)].
Radioimmunologically estimated diurnal profiles of 17-hydroxyprogesterone (17-OHP) showed clearly increased values in 15 patients with adrenogenital syndrome aged 9-19 years who had been treated for at least 4 1/2 years with cortisol. Increases were pronounced in the morning: at 8 hours 58.6 nmol/l, at 12 hours 22.2 nmol/l, at 18 hours 23.7 nmol/l on average. By changing cortisol medication, in particular due to split doses, morning 17-OHP peak values could be lowered and the whole daily profile could be improved: at 8 hours 17.9 nmol/l, at 12 hours 9.3 nmol/l, at 18 hours 8.1 nmol/l on average. The total cortisol dosage had to be increased only marginally from an average of 26.7 to 30 mg/m2 body surface, however, the evening dosage was increased from 20% to 38% on average of the total dose. Measurement of serum 17-OHP diurnal profile is thus advantageous in treatment of adrenogenital syndrome with cortisol when compared to values obtained from 24-hour urine collections.
D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000097:blood* / Q000188:drug therapy; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D006908:Hydroxyprogesterones / Q000097:blood*; D008297:Male; D011863:Radioimmunoassay; D013997:Time Factors
D006908:Hydroxyprogesterones; D006854:Hydrocortisone
Adrenogenitales Syndrom. Therapeutische Einstellung anhand des Tagesprofils des 17-Hydroxyprogesterons im Serum.